Oral melphalan plus high-dose dexamethasone as first-line therapy for patients with primary light chain amyloidosis / 中华血液学杂志
Chinese Journal of Hematology
; (12): 641-644, 2018.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-1011830
Biblioteca responsável:
WPRO
ABSTRACT
Objective:
To evaluate the response of oral melphalan plus high-dose dexamethasone (MDex) for patients with primary light chain amyloidosis (pAL).Methods:
Clinical data, hematological and organ responses, and survival of 76 patients with pAL who had received MDex from January 2009 to July 2017 were retrospectively analyzed.Results:
Of 76 patients (47 males and 29 females with the median age of 56 [range, 20-74] years old), 19.70% patients were defined as Mayo 2004 stage 3, involvement of more than or two organs was presented in 65 (85.53%) patients. Among 60 response evaluable patients, overall hematological response was 48.33% with complete response of 20.00% and very good partial response of 20.00%, respectively. The median time to the hematological response was 5 (range, 1-15) months. 36.67% patients achieved organ response. After the median follow up of 23(range, 1-113) months for surviving patients, median progression-free survival (PFS) and overall survival (OS) were 34 and 43 months, respectively. In a three months landmark analysis, the median rates of PFS and OS were 46 and 65 months, respectively. The median OS rates of patients with Mayo 2004 stage 3 and non Mayo 2004 stage 3 were 5 and 65 months (P=0.001), respectively.Conclusions:
MDex was an effective treatment for patients with early stage pAL, but was not suitable for those with severe cardiac involvement.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Dexametasona
/
Estudos Retrospectivos
/
Resultado do Tratamento
/
Combinação de Medicamentos
/
Amiloidose de Cadeia Leve de Imunoglobulina
/
Amiloidose
/
Melfalan
Limite:
Adulto
/
Idoso
/
Feminino
/
Humanos
/
Masculino
Idioma:
Chinês
Revista:
Chinese Journal of Hematology
Ano de publicação:
2018
Tipo de documento:
Artigo